LifeNet Health, which provides transplant solutions like organ procurement and cellular therapies, plans to fold Vivo Biosciences’ products into the company’s “life sciences” division. This newly-created division will focus on personalized medicine.
Vivo Biosciences’ primary development was HuBiogel, a substance the company created to bind cells together. Vivo Biosciences developed these cells into tumor models, which it leveraged for drug efficacy and toxicity testing.
“These advances will enable researchers to better predict which medicines will be effective in fighting diseases such as cancer, saving time in treatments for patients,” Rony Thomas, president and CEO of LifeNet Health, told the Birmingham Business Journal.
More articles on health IT:
National Institute of Standards and Technology drafts reference resource for employers looking to recruit, retain cybersecurity workforce
Johns Hopkins lays foundation for ‘data-intensive brain science’
Survey: 51.4% of patients have received email, texts from a physician
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.